Ann Lab Med.  2021 Jan;41(1):16-24. 10.3343/alm.2021.41.1.16.

Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases

  • 1Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan
  • 2NAFLD Research Center, Division of Medicine, University of California, San Diego, La Jolla, California, USA


An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review, we discuss the role of M2BPGi in diagnosing liver fibrosis in chronic hepatitis B and C, chronic hepatitis C after sustained virologic response (SVR), and nonalcoholic fatty liver disease (NAFLD). M2BPGi predicts not only liver fibrosis but also the hepatocellular carcinoma (HCC) development and prognosis in patients with chronic hepatitis B and C, chronic hepatitis C after SVR, NAFLD, and other chronic liver diseases. M2BPGi can also be used to evaluate liver function and prognosis in patients with cirrhosis. M2BPGi levels vary depending on the etiology and the presence or absence of treatment. Therefore, the threshold of M2BPGi for diagnosing liver fibrosis and predicting HCC development has to be adjusted according to the background and treatment status.


Mac-2 binding protein glycosylation isomer; Liver fibrosis; Threshold; Hepatocellular carcinoma; Chronic hepatitis C; Chronic hepatitis B; Sustained virologic response; Nonalcoholic fatty liver disease
Full Text Links
  • ALM
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: